Cancer screening and management in the transgender population: Review of literature and special considerations for gender affirmation surgery

Figure 1 The preferred reporting items for systematic reviews and meta-analyses flowchart for overall cancer screening and manage-ment in the gender affirming surgery population.

Figure 2 The preferred reporting items for systematic reviews and meta-analyses charts for the breast screening and management. A: The preferred reporting items for systematic reviews and meta-analyses (PRISMA) flowchart for articles about breast cancer screening; B: PRISMA flowchart for breast cancer management.

Figure 3 Study design for male to female gender affirming surgery patients. MtF: Male to female; IDC: Invasive ductal carcinoma; DCIS: Ductal carcinoma in situ; BIA: Breast implant associated.

Figure 4 Study design for female to male gender affirming surgery patients. FtM: Female to male; IDC: Invasive ductal carcinoma; DCIS: Ductal carcinoma in situ; AR: Androgen receptor.

Figure 5 The preferred reporting items for systematic reviews and meta-analyses flow diagram indicated database search records and inclusion decision steps. The diagram includes records regarding endometrial and cervical cancer studies.

Figure 6 The preferred reporting items for systematic reviews and meta-analyses flow diagram indicated database search records and inclusion decision steps. The diagram includes records regarding ovarian cancer studies.

Figure 7 The preferred reporting items for systematic reviews and meta-analyses flow diagram indicated database search records and inclusion decision steps. The diagram includes records regarding prostate cancer studies.

Figure 8 The preferred reporting items for systematic reviews and meta-analyses flow diagram indicated database search records and inclusion decision steps. The diagram includes records regarding testicular cancer studies. TGNC: Transgender and gender nonconforming.